IGLC2 and arrhythmogenic right ventricular cardiomyopathy: Cardiomyopathy is a common adverse effect of chemotherapeutic agents (i.e., trastuzumab and doxorubicin) for BC (90–92), which may partially explain why IGLC2 is related to HCM, DCM, and ARVC.